Larimar Therapeutics Inc Quick Ratio (LRMR) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Larimar Therapeutics Inc   (NASDAQ: LRMR)

Larimar Therapeutics Inc 's Quick Ratio

LRMR's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Larimar Therapeutics Inc 's Cash & cash equivalent grew by 9.73 % in the Q2 2026 sequentially, while Current Liabilities decreased, this led to improvement in Larimar Therapeutics Inc 's Quick Ratio to 6.44, Quick Ratio remained below Larimar Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 159 other companies have achieved higher Quick Ratio than Larimar Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 593, from total ranking in the first quarter 2026 at 674.

Explain Quick Ratio?
How much Cash & cash equivalents LRMR´s has?
What are LRMR´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LRMR Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 28.21 % 115.76 % 166.03 % 177.04 % 25.97 %
Y / Y Cash & cash equivalent Change 58.73 % 27.21 % -25.4 % -13.88 % -38.72 %
Quick Ratio MRQ 6.44 4.2 2.11 3.89 5.2
LRMR's Total Ranking # 593 # 674 # 835 # 676 # 454
Seq. Current Liabilities Change -28.46 % -26.3 % 43.62 % 69.3 % 20.4 %
Seq. Cash & cash equivalent Change 9.73 % 46.42 % -21.99 % 26.65 % -12.06 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 160
Healthcare Sector # 252
Overall Market # 593


Quick Ratio Statistics
High Average Low
32.72 11.39 2.11
(Jun 30 2014)   (Dec 31 2025)




Financial Statements
Larimar Therapeutics Inc 's Current Liabilities $ 34 Millions Visit LRMR's Balance sheet
Larimar Therapeutics Inc 's Cash & cash equivalent $ 220 Millions Visit LRMR's Balance sheet
Source of LRMR's Sales Visit LRMR's Sales by Geography


Cumulative Larimar Therapeutics Inc 's Quick Ratio

LRMR's Quick Ratio for the trailling 12 Months

LRMR Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 114.52 % 119.61 % 112.62 % 97.79 % 78.63 %
Y / Y Cash & cash equivalent TTM Growth 7.22 % -15.51 % -27.62 % -11.95 % 7.47 %
Quick Ratio TTM 3.82 3.53 3.83 5.54 7.64
Total Ranking TTM # 3759 # 3740 # 2395 # 2935 # 2399
Seq. Current Liabilities TTM Growth 4.08 % 16.15 % 34.2 % 32.24 % 6.55 %
Seq. Cash & cash equivalent TTM Growth 12.49 % 7.05 % -7.12 % -4.14 % -11.36 %

Quick ratio ranking by company, industry and sector >> Back to LRMR Financial Strength Comparisons >> Go to Compare LRMR Quick Ratio to its Competitors

On the trailing twelve months basis LRMR Cash & cash equivalent soared by 58.73 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Larimar Therapeutics Inc 's Quick Ratio to 3.82, Quick Ratio remained below LRMR average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 426 other companies have achieved higher Quick Ratio than Larimar Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3740 to 3759.

Explain Quick Ratio?
How much Cash & cash equivalents LRMR´s has?
What are LRMR´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 427
Healthcare Sector # 869
Within the Market # 3759


trailing twelve months Quick Ratio Statistics
High Average Low
14.21 10.31 3.53
(Mar 31 2016)   (Mar 31 2026)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Sellas Life Sciences Group Inc   17.29 $ 138.443  Millions$ 8.006  Millions
Whitehawk Therapeutics Inc   17.17 $ 190.000  Millions$ 11.069  Millions
Forte Biosciences Inc   17.12 $ 347.331  Millions$ 20.289  Millions
Ovid Therapeutics Inc   17.01 $ 169.769  Millions$ 9.980  Millions
Bioage Labs Inc   16.59 $ 318.745  Millions$ 19.217  Millions
Olema Pharmaceuticals Inc   16.48 $ 873.571  Millions$ 53.014  Millions
Erasca Inc   16.41 $ 610.496  Millions$ 37.200  Millions
Janux Therapeutics Inc   16.14 $ 970.913  Millions$ 60.152  Millions
Edgewise Therapeutics inc   15.86 $ 460.709  Millions$ 29.042  Millions
Corvus Pharmaceuticals Inc   15.74 $ 215.200  Millions$ 13.672  Millions
Telomir Pharmaceuticals Inc   15.55 $ 5.170  Millions$ 0.332  Millions
Rapport Therapeutics Inc   15.34 $ 436.077  Millions$ 28.424  Millions
Lb Pharmaceuticals Inc  15.32 $ 369.576  Millions$ 24.128  Millions
Anixa Biosciences Inc   15.09 $ 26.330  Millions$ 1.745  Millions
Siga Technologies Inc  14.99 $ 117.584  Millions$ 7.845  Millions
Vyne Therapeutics Inc   14.87 $ 22.925  Millions$ 1.542  Millions
Alto Neuroscience Inc   14.64 $ 243.733  Millions$ 16.652  Millions
Tenax Therapeutics Inc   14.62 $ 118.000  Millions$ 8.073  Millions
Jade Biosciences Inc   14.61 $ 461.205  Millions$ 31.570  Millions
Immunome Inc   14.56 $ 519.996  Millions$ 35.713  Millions
Sensei Biotherapeutics Inc   14.54 $ 186.441  Millions$ 12.824  Millions
Cytokinetics Incorporated  14.39 $ 2,610.415  Millions$ 181.429  Millions
Canton Strategic Holdings Inc   14.18 $ 37.242  Millions$ 2.626  Millions
An2 Therapeutics Inc   14.04 $ 78.387  Millions$ 5.585  Millions
Aclaris Therapeutics Inc   13.97 $ 394.443  Millions$ 28.241  Millions
Pmv Pharmaceuticals Inc   13.85 $ 146.393  Millions$ 10.568  Millions
Generate Biomedicines Inc   13.76 $ 779.456  Millions$ 56.636  Millions
First Tracks Biotherapeutics Inc   13.50 $ 168.018  Millions$ 12.447  Millions
Arrivent Biopharma inc   13.41 $ 373.401  Millions$ 27.844  Millions
Cogent Biosciences Inc   13.36 $ 792.300  Millions$ 59.296  Millions

Date modified: 2026-08-31T03:09:44+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.